Stockreport

Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF KEY FACTSTwo late-breaking presentations from the landmark OCEANIC-STROKE study will provide new insights into ischemic strokes that occurred during the trial, as well a [Read more]